Sohonos 10 mg Oral Capsule
RxNorm 2663974

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2663974 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: sohonos 10 mg Oral Capsule.

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
Palovarotene 10 mg Oral Capsule [Sohonos]
AUI:12850162
View
PSN
Sohonos 10 mg Oral Capsule
AUI:12850164
View
SY
Sohonos 10 mg Oral Capsule
AUI:12850163
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDPrescribable

Semantic Branded Drug (SBD):
Palovarotene 10 mg Oral Capsule [Sohonos]
(Atom ID: 12850162)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
palovarotene 10 MG Oral Capsule [Sohonos]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2663974
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12850162
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
2663974
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2663971} 2663954
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2663971} 2663954
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
10 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{2663971} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXTERM FORM
Cap
The RxTerm dose form name for this drug
PSNPrescribable

Prescribable Name (PSN):
Sohonos 10 mg Oral Capsule
(Atom ID: 12850164)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
sohonos 10 MG Oral Capsule
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2663974
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12850164
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2663974
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Sohonos 10 mg Oral Capsule
(Atom ID: 12850163)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Sohonos 10 MG Oral Capsule
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2663974
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12850163
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2663974
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Palovarotene


Palovarotene is used to reduce the number of new heterotrophic ossification (bony formations in muscle and soft tissue) in patients with fibrodysplasia ossificans progressive (FOP) in females aged 8 years or older or females aged 10 years or older. Palovarotene is in a class of medications called retinoids. It works by stopping the signaling responsible for heterotophic ossification.
[Learn More]


* Please review the disclaimer below.